Semaglutide Manufacturers

Joyous has been researching small molecule peptide products for a long time. In response to customer requests, we have classified peptides separately. Semaglutide currently has two models on the market, one is an injection and the other is an oral drug combined with SNAC. For tablets, Joyous has the raw materials for both semaglutide, but liquid export may require some conditions.

Product Name

Semaglutide

Specification

99.99%

CAS No

910463-68-2

Appearance

White powder, odorless, easily soluble in water, the solution is colorless or light yellow transparent liquid

Molecular Formula

C187H291N45O59

MOQ

GET A QUOTE

Add to Quote List View Quote List

Desciption

Product information
What is Semaglutide powder?
Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analog developed by Denmark's Novo Nordisk. Semaglutide is based on the basic structure of liraglutide. The developed long-acting dosage form is more effective in treating type 2 diabetes. Novo Nordisk has completed six Phase IIIa studies of semaglutide injection and submitted a new drug registration application for semaglutide once-weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) has also been submitted to the European Medicines Agency (EMA). Semaglutide was prepared by solid-liquid phase synthesis. The linear peptide Aib8, Arg34GLP-1(7-37) and aliphatic side chain acylating agent were prepared by solid-phase synthesis method. The linear peptide Lys26 was modified with the synthesized aliphatic chain acylating agent under alkaline conditions to obtain Soma. glutide, and the bioactivity of homemade samples was measured by time-resolved fluorescence resonance energy transfer immunoassay.
As a new drug in the GLP-1 receptor agonist class, semaglutide is injected subcutaneously once a week. Compared with liraglutide, liraglutide has a longer fatty chain and increased hydrophobicity, but semaglutide has a shorter The PEG modification of the chain greatly enhances the hydrophilicity. After modification, PEG can not only bind tightly to albumin, mask the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, extend biological half-life, and achieve long circulation. Novo Nordisk's semaglutide beats DPP-4's sitagliptin and long-acting exenatide, the originator of GLP-1. In the trial, high-dose Soma reduced A1C by 1.6% and reduced body weight by up to 6kg. This trial of semaglutide examined the effectiveness and safety of 1.0 mg semaglutide compared with weekly injections of 2.0 mg exenatide in 813 patients with type 2 diabetes. The trial period lasted 56 weeks. Take 1-Chemicalbook2 anti-diabetic drugs orally at the same time. In December 2017, the FDA officially approved the once-weekly GLP-1 antidiabetic drug semaglutide developed by Novo Nordisk for marketing under the trade name Ozempic. According to clinical trial data, Ozempic can reduce HbA1c levels compared with placebo, Merck's Januvia, AstraZeneca's Bydureon and Sanofi's Lantus. The drug has also shown the ability to help patients lose weight. As a leader in the field of diabetes, Novo Nordisk not only dominates the world in the field of insulin, but also develops human glucagon-like peptide-1 (GLP-1) analogue Liraglutide (trade name: Liraglutide) : Victoza), which has dominated the GLP-1 market since its launch in 2009. In 2016, global sales reached US$3.2 billion, which can be described as fruitful results. The liraglutide compound has expired, and generic drug companies are eyeing it. In order to prevent problems before they occur, Novo Nordisk has already prepared the next generation of liraglutide, which is semaglutide. From a structural point of view, Semeglutide replaces Ala with Aib at position 8 of the GLP-1 (7-37) chain, replaces Lys with Arg at position 34, and connects Lys at position 26 to an octadecanoic acid fatty chain. Compared with Liraglutide, Semeglutide has a longer aliphatic chain and increased hydrophobicity. However, Semeglutide has been modified with short-chain PEG and its hydrophilicity is greatly enhanced. After modification, PEG can not only bind tightly to albumin, mask the hydrolysis site of DPP-4 enzyme, but also reduce renal excretion, extend biological half-life, and achieve long circulation. According to analysis, Ozempic is expected to become one of the best-selling drugs in 2017. Novo Nordisk forecasts drug sales of $2.2 billion in 2022. At the same time, the oral tablet developed by Novo Nordisk has been approved for marketing in Japan. The oral dosage form uses a new pharmaceutical excipient, SNAC (available at Joyous), which is very popular in Japan and has received excellent feedback.
Joyous Semaglutide powder specification

Terms	Standard	Terms	Standard
Product Name	Semaglutide	Appearance	Off white powder
Assay	99.99%	Loss on Drying	≤2%
Total Heavy Metals	≤10 ppm	Ash	≤2%
As	≤0.5ppm	Total Plate Count	≤750 cfu/g
Pb	≤0.5ppm	Yeast and Mold	≤100 cfu/g
Cd	≤0.5ppm	Coliforms	Negative
Hg	≤0.1ppm	E.Coli	Negative
Packing	Pack in 25kgs paper-drums, inner by double plastic bag	Shelf life	24 months under the above condition, and in its original package

Some introduction to semaglutide
Please note here that Joyous's semaglutide is not sold to any individuals (C-end users), but only to enterprises and research institutions (B-end users). Generally speaking, Joyous's products belong to the raw material series and require further processing. You can take it directly after changing the dosage form.
Semaglutide is a second-generation GLP-1 (glucagon-like peptide-1) analog developed by diabetes giant Novo Nordisk. After dulaglutide, lixisenatide and benaglutide, it is the seventh GLP-1 receptor agonist in the world and the third long-acting GLP-1 weekly preparation in the world.
Joyous's brief introduction is divided into two parts, namely semaglutide liquid injection and semaglutide powder preparation (tablets, etc.).

The first is injection. According to the results of a post hoc analysis of the SUSTAIN 1~5 study announced at the 53rd European Association for the Study of Diabetes Annual Meeting (EASD2017) on September 12, 2017, patients with type 2 diabetes received Soma once a week. The hypoglycemic and weight loss effects of glutide injection treatment were significantly better than those of placebo, sitagliptin, insulin glargine U100 or extended-release exenatide. In the "head-to-head" PK with dulaglutide, the most popular long-acting GLP-1 receptor agonist in 2022, semaglutide also won in both indicators of blood sugar reduction and weight loss. Liraglutide achieved a 5% weight loss effect in patients with BMI ≥ 30, and semaglutide achieved a weight loss effect of more than 15% in a phase II study; Novo Nordisk announced the first-line results of a phase II study It has been shown that once daily subcutaneous injection of semaglutide 0.05 ~ 0.4mg/d, after 52 weeks of treatment and 7 weeks of follow-up, obese patients with a baseline average weight of 111kg can lose 16.2% (17.8kg), while exercise, The diet plus placebo group lost only 2.3% of their weight. This is why semaglutide is so popular. It is not only good news for diabetics, but also the first choice for people who exercise and lose weight.
Semaglutide is also the third antidiabetic drug to show cardiovascular benefits. Semaglutide reduced the risk of the primary composite endpoint (first incident cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 26% compared with placebo. After 2 years of treatment, semaglutide significantly reduced the risk of nonfatal stroke by 39%, nonfatal myocardial infarction by 26%, and cardiovascular death by 2%.
The following is an oral dosage form. The liquid is an injection with the trade name Ozempic approved by the FDA in December 2017. The oral dosage is a tablet with the trade name Rybelsus approved by the FDA in September 2019 as the first oral GLP-1 analogue. , it was also approved for listing by MHLW (Japanese Ministry of Health, Labor and Welfare) in 2020, and applied to CDE for listing in April 2020.
Semaglutide oral dosage forms rely on SNAC. As a penetration enhancer, SNAC promotes the monomerization of semaglutide, making it more permeable. For the semaglutide molecule, most semaglutide exists as oligomers in the stomach; SNAC triggers a change in polarity of the solution containing the dissolving tablet, weakening the necessary for oligomerization. hydrophobic interactions. Because SNAC is lipophilic, it effectively inserts into the cell membrane of the gastric epithelium, changing the inherent integrity of cholesterol phospholipids and proteins, thereby affecting the fluidity of the cell membrane. Studies in SD rats confirmed that SNAC enhanced the intracellular uptake of semaglutide by gastric epithelial cells, thus supporting the idea that SNAC promotes the transcellular transport of semaglutide and effectively increases semaglutide in the stomach. The local pH value around the peptide molecule prevents the degradation of the peptide by pepsin. With the help of a concentration gradient on the cell membrane surface, semaglutide penetrates the gastric mucosa and is absorbed into the blood. The pyloric ligation test on experimental dogs found that: ligation/not After semaglutide tablets were administered to ligated dogs, the plasma concentrations of semaglutide were similar, confirming that semaglutide tablets are mainly absorbed in the stomach.
In addition to oral semaglutide, Joyous believes that oral administration of peptides has gradually become the future trend in the development of peptide drugs. Although only semaglutide tablets are currently approved for marketing, its subversive effect on the drug administration routes in the field of peptides Enough to be inspiring. As a penetration enhancer, SNAC has great advantages in leading the development of oral peptides from scratch, but whether it can replicate the excellent performance of semaglutide tablets to other peptide drugs requires careful consideration.
Because semaglutide has a longer half-life and a wider therapeutic window, it has laid a solid foundation for its safe and effective clinical results. From the early research and development process of Emisphere, we can see that SNAC is not omnipotent. We need to better understand its principle of action to find more ideal usage scenarios and more matching partner drugs for it. In terms of raw materials and excipients, Joyous is undoubtedly China's One of the most comprehensive and professional suppliers in the country.
Package and delivery

Delivery
1-80kg	80-300kg	More than 300kg
More suitable for express transportation, door-to-door	More suitable for air transportation,airport-to-airport	More suitable for ocean transportation,port-to-port
7-10 days for delivery time	3-4 days for delivery time	20-40 days for delivery time

What service we can provide
Joyous Health provides Semaglutide powder OEM services. We can customize formulas for customers, private labels, capsules, tablets, soft capsules and sachets, low MOQ, which is suitable for direct sales by brands. Our OEM product shipping channels are stable and delivery times are fast and worthy of customers' trust, we have served more than 300 brands.

Joyous Health Factory information and certifications
Xi'an Joyous Health Biotechnology Co., Ltd. was established in 2011. Over the past 12 years, Joyous Health has obtained ISO 9001, FDA, ISO 22000, and GMP certifications.
Joyous Health has an advanced laboratory to control quality, so that each batch of products undergoes strict testing, and has professional R&D personnel to provide customized product services.
For more details please click here

Where to buy Semaglutide powder?
We offer the best Semaglutide powder at the most competitive price.Semaglutide Powder bulk and wholesale powder have been 3rd lab-tested and verified for both product purity and identity.
We also provide Semaglutide powder in bulk order or wholesale according to client needs. Just submit the requirements in the bottom form, we will reply soon!

Contacts: Faith Feng
Email:[email protected]
Tel and Whatsapp:+86 17391747738

REQUEST MORE DETAILS

Please fill out the form below and click the button to request more information about

We provide high-quality products and services, as well as customized pellets. We are a professional ingredient supplier and solution provider.

Contact: Xi'an international enterprise center B building, Fengcheng 4 road, Xi'an City, Shaanxi province, China; [email protected]; +86 17391747738

Follow Us

Lates News: Don't miss our news subscription, please fill in the form below.

Leave Message

FirstName*

LastName*

Email*

Tel No.

Message

We use Cookie to improve your online experience. By continuing browsing this website, we assume you agree our use of Cookie.